Meeting highlights from the CHMP meeting in November 2016
Nine medicines recommended for approval, including three biosimilars
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval at its November meeting.
The CHMP recommended granting a marketing authorisation for Afstyla (lonoctocog alfa) for the prevention and treatment of bleeding in patients with haemophilia A.
Vemlidy (tenofovir alafenamide) received a positive opinion from the CHMP for the treatment of chronic hepatitis B.
Fiasp (insulin aspart) was recommended for approval by the CHMP for the treatment of diabetes.
Suliqua (insulin glargine/lixisenatide) was recommended for approval for the treatment of type 2 diabetes.
Three biosimilar medicines were recommended for approval by the Committee: Lusduna (insulin glargine) for the treatment of diabetes, and Movymia and Terrosa (both containing teriparatide) for the treatment of osteoporosis. A biosimilar medicine is a biological medicine that is similar to another biological medicine.
Two generic medicines were recommended for approval: Darunavir Mylan (darunavir) for the treatment of human immunodeficiency virus (HIV-1) infection and Tadalafil Generics (tadalafil) for the treatment of pulmonary arterial hypertension.
Five recommendations on extensions of therapeutic indications
The Committee recommended extensions of indications for Arzerra, Caprelsa, Humira, Nimenrix and Vimpat.
Translarna: renewal of conditional marketing authorisation
The CHMP completed its scientific assessment of the annual renewal of the conditional marketing authorisation for Translarna (ataluren) and recommended that the conditional marketing authorisation be renewed.
As part of the CHMP assessment, the Committee reviewed all available data, including the results of a study performed by the marketing authorisation holder as a requirement of the conditional marketing authorisation after initial approval. Although the data available to date continue to indicate that Translarna slows the progression of the disease and there are no major safety concerns, the Committee considered that further comprehensive data are still needed to fully confirm that the benefit-risk balance of the medicine is positive.
The CHMP has therefore requested that the marketing authorisation holder for Translarna conducts a new 18-month randomised, placebo-controlled study in patients with Duchenne muscular dystrophy, followed by an 18-month period where all patients will be switched to Translarna. The study results are expected to be available in the first quarter of 2021.
Translarna is used to treat patients aged five years and older with Duchenne muscular dystrophy, a serious and rare condition for which no authorised treatments are currently available. The medicine is intended for use in patients who are able to walk and whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the gene for the muscle protein dystrophin.
Conditional approval allows CHMP to recommend a medicine for marketing authorisation where the benefit to public health of its immediate availability on the market outweighs the risk inherent in the fact that additional data are still required. These medicines are subject to post-authorisation obligations that aim to generate comprehensive data on the medicine. Conditional marketing authorisations are valid for one year and can be renewed or converted to a standard five-year marketing authorisation when the additional data generated confirm that the benefit-risk balance of the medicine is positive.
The assessment report on the renewal of the conditional marketing authorisation for Translarna will be published after the European Commission issues its decision on the renewal.
More information on CHMP's November meeting can be found on EMA's website.